COMMUNIQUÉS West-GlobeNewswire
-
ITM and AtomVie Global Radiopharma Enter Supply Agreement for n.c.a. Lutetium-177
19/11/2026 -
Harmony Biosciences to Participate in Upcoming Investor Conferences
19/11/2026 -
VivoSim Labs Signs Seven-Figure Agreement with a Top-10 Global Pharmaceutical Company; Expects to Exceed Its 500%+ Revenue Growth Guidance for Fiscal 2027
19/11/2026 -
NewGenIvf Group Limited Announces Pricing of $2.5 Million Underwritten Offering
19/11/2026 -
SS Innovations Announces World’s First Dual-Console, Beating-Heart TECAB Surgery Utilizing All Five Arms of the SSi Mantra Surgical Robotic System
19/11/2026 -
RenovoRx Appoints Interventional Oncology Medtech Leader Richard Stark to its Board of Directors
19/11/2026 -
Conexeu Sciences Appoints Life Sciences Veteran Daniel M. Bradbury as Chairman of the Board of Directors
19/11/2026 -
ICU Medical to Participate at the Piper Sandler 38th Annual Healthcare Conference
19/11/2026 -
Ethics Approval for Amplia’s Accent-Mini Trial
19/11/2026 -
Tria Federal Appoints Ryan Hill as Chief Financial Officer
19/11/2026 -
Konica Minolta Healthcare Partners with National Rural Healthcare Association to Help Address the Unique Challenges of Rural Hospitals
19/11/2026 -
Philips introduces Advanced Image Insights for advanced visualization and AI orchestration
19/11/2026 -
ALK presents new data at FAAM-EUROBAT-ISMA 2026: Data from a comparative study using adrenaline trainer devices suggests EURneffy® nasal adrenaline spray is more suitable for public places than an adrenaline auto-injector
19/11/2026 -
Asgard Therapeutics awarded €2.5m EIC Accelerator grant to advance lead program AT-108 toward the clinic
19/11/2026 -
A Race Against Blindness Brings Back “Miles, Magic & Mochas” Fundraiser for the Holiday Season
19/11/2026 -
HUTCHMED Announces China NMPA Approval of SYVIK® (sovleplenib) for the Treatment of Primary Immune Thrombocytopenia and Warm Antibody Autoimmune Hemolytic Anemia
19/11/2026 -
Novartis projects +5% cc¹ sales CAGR through 2031 and sustained mid-single-digit growth over the long term
19/11/2026 -
Communiqué de presse : VaxRabeo, le vaccin contre la rage de nouvelle génération de Sanofi, approuvé dans l’UE pour tous les âges
19/11/2026 -
Press Release: Sanofi’s next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages
19/11/2026
Pages